Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cu(II)ATSM Phase 1 in ALS/MND
NCT02870634Phase 1Completed
- Sponsor
- Vivat Therapeutics
- Start
- Nov 2016
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CuATSM in amyotrophic lateral sclerosis (ALS), sponsored by Vivat Therapeutics. Primary endpoint: Recommended Phase 2 Dose at 24 months. Started Nov 2016; status: completed.
02
Drugs
CuATSM
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT02870634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02870634.